Please assess the completion status of the following clinical trial:

Trial Title: Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent has been obtained.~* Adults over 18 years of age.~* Histologically or cytologically proven adenocarcinoma of the prostate.~* Stage IV disease as evidenced by soft tissue, visceral and/or bony metastasis must be Response Evaluation Criteria in Solid Tumors (RECIST) evaluable on CT scan and/or bone scan~* Progressive disease while receiving hormonal therapy or after surgical castration documented by at least one of the following:~  1. Increase in measurable disease per RECIST 1.1,~ 2. Appearance of new lesions on bone scan consistent with progressive prostate cancer (\>2 new lesions on bone scans if this is the only measure of PD),~ 3. rising PSA defined as 2 sequential increases above a previous lowest reference value.~     * Each value must be obtained at least 1 week apart.~* PSA at least 2 ng/mL~* Received prior docetaxel chemotherapy~* Received prior abiraterone acetate, but not within the 3 months prior to study drug dosing.~* Testosterone level \<50 ng/mL. Patients receiving Leutinizing Hormone Releasing Hormone (LHRH) agonists or antagonists must be continued to maintain castrate levels of testosterone while on study.~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.~* Adequate hematologic function:~  1. platelet \>100, 000/uL;~ 2. neutrophil count of \>1500 cell/mm3;~ 3. hemoglobin \>9.0 g/dL)~* Adequate renal function (Creatinine clearance \> 50 mL/min)~* Adequate potassium level (\> 3.5 mEq/dL)~* Adequate hepatic function~  1. bilirubin \< 1.5 X upper limit of normal (ULN),~ 2. alanine aminotransferase (ALT) \< 1.5 X ULN,~ 3. aspartate aminotransferase (AST) \< 1.5 X ULN.~ 4. serum albumin of ≥ 3.0 g/dL.~* Controlled blood pressure, defined as blood pressure ≤ 140/90 on average (3 separate readings taken at screening visit in a relaxed clinical environment and averaged)~* Must be able to take oral medication without crushing, dissolving or chewing tablets~* Willing to take abiraterone acetate on empty stomach;~  (1) no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken.~* Patients must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.~* Written authorization for use and release of health and research study information has been obtained.~* Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection during the study and for 1 week after the last dose of abiraterone acetate.~Exclusion Criteria:~* Surgery or radiation therapy within 2 weeks, or~* Cytotoxic anti-cancer therapy within 3 weeks, or~* Non-cytotoxic anti-cancer therapy within 2 weeks, or 5 half-lives (whichever is shorter) of Study Day 1.~* Prior radiotherapy to ≥ 40% of bone marrow.~* Prior treatment with Radium 223.~* Use of an investigational therapeutic agent within 30 days.~* Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents.~* Prior treatment with cabazitaxel.~* Known chronic infection with human immunodeficiency virus (HIV).~* Known active, or symptomatic, brain metastasis.~* Blood pressure \>140/90 on average (3 separate readings taken at screening visit in a relaxed clinical environment and averaged).~* History of autoimmune disorder requiring daily corticosteroid therapy of greater than prednisone 10mg daily, or its equivalent.~* Baseline peripheral edema \> grade 3.~* Pre-existing diarrhea uncontrolled with supportive care;~* Prior hemorrhagic diarrhea due to ulcerative colitis, inflammatory bowel disease or other cause;~* Active, uncontrolled peptic ulcer disease even in the setting of proton-pump inhibitor or Histamine2-blocker use.~* Pre-existing peripheral neuropathy grade \> 2.~* Documented hypersensitivity (CTCAE grade \> 2) to any drug containing polysorbate 80.~* Have known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipients.~* Contraindications to steroid use.~* Need for medications that strongly induce or inhibit cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2D6 (CYP2D6) activity. (see section 7.2.3 for details)~* Serious infection requiring parenteral antibiotics within 14 days of enrollment.~* Poorly controlled diabetes (Hgb A1C \>9).~* Active or symptomatic viral hepatitis or Chronic liver disease, including Child-Pugh Class B and C liver disease.~* History of pituitary or adrenal dysfunction.~* Clinically significant heart disease as evidenced by:~  1. myocardial infarction, or~ 2. arterial thrombotic events in the past 6 months,~ 3. severe or unstable angina, or~ 4. New York Heart Association Class III-IV heart disease, or~ 5. cardiac ejection fraction measurement of \<50% at baseline.~* Consumption of food or beverages containing grapefruit juice within 7 days of study drug dosing~* Use of a first-generation anti-androgen such as:~  1. bicalutamide within 6 weeks of study drug dosing, or~ 2. flutamide within 4 weeks of study dosing.~* Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Cabazitaxel with Abiraterone Acetate (Type: EXPERIMENTAL): Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
- Cabazitaxel Alone (Type: ACTIVE_COMPARATOR): Cabazitaxel administered as a single intravenous dose every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).